The aim of this study was to investigate the risk of neoplasms later in life for patients treated with recombinant human GH (rhGH) in childhood due to isolated growth hormone deficiency (GHD), small for gestational age (SGA), or idiopathic short stature (ISS). Here, GH1 is linked to neoplasm.